1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,041 | 0,196 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Probiotix Health PLC - Director/PDMR Shareholding | 1 | RNS | ||
| 21.01. | ProBiotix Health says annual gross profit jumps as sales increase 45% | 2 | Alliance News | ||
| PROBIOTIX HEALTH Aktie jetzt für 0€ handeln | |||||
| 21.01. | Probiotix Health PLC - Trading Update | 1 | RNS | ||
| 03.11.25 | Probiotix Health PLC - Move from Access to Apex Segment of Aquis | 1 | RNS | ||
| 23.10.25 | Probiotix Health PLC - Appointment of Aquis Corporate Adviser | 8 | RNS | ||
| 20.10.25 | ProBiotix partners with Wellizen on new cardiometabolic health capsule | 1 | Alliance News | ||
| 20.10.25 | Probiotix Health PLC - New Commercial Partnership in Australia | 1 | RNS | ||
| 14.10.25 | ProBiotix partners with RevivaBio on new cholesterol-lowering product | 1 | Alliance News | ||
| 14.10.25 | Probiotix Health PLC - Director/PDMR Shareholding | 1 | RNS | ||
| 14.10.25 | Probiotix Health PLC - New Commercial Partnership in Sweden | 1 | RNS | ||
| 13.10.25 | ProBiotix Health says sales rise amid "well received" new products | 2 | Alliance News | ||
| 13.10.25 | Probiotix Health PLC - Q3 2025 Trading Update and Grant of Options | 1 | RNS | ||
| 08.09.25 | ProBiotix Health narrows loss amid 'record' first half performance | 5 | Alliance News | ||
| 08.09.25 | Probiotix Health PLC - Unaudited Interim Results to 30 June 2025 | 1 | RNS |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MUSTGROW BIOLOGICS | 0,404 | 0,00 % | Lösung für Milliarden-Dollar-Problem: MustGrow Biologics validiert Geschäftsmodell - revolutionäre Meldung auch für Bayer und Corteva Agriscience | Raps ist für Kanada fast das, was Erdöl für Saudi-Arabien ist: Ein wirtschaftlicher Motor von gigantischem Ausmaß. Mit einem geschätzten Produktionswert von rund 14 Mrd. CAD im Jahr 2025 ist die gelb... ► Artikel lesen | |
| MAAT PHARMA | 7,000 | -1,13 % | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| OPTIBIOTIX HEALTH | 0,084 | 0,00 % | OptiBiotix Health hails record start to 2026 after securing new orders | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report |
Das Unternehmen PROBIOTIX HEALTH PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,064 Euro und damit +0,79 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROBIOTIX HEALTH PLC finden Sie auf Wallstreet Online.